EUVIMEDEUVIMED entdecken
Crossref

Ultrasound‐Triggered Dinuclear Iridium Sonosensitizer Activates Paclitaxel Prodrug for Synergistic Sonodynamic‐Chemotherapy

Jianxin Rong, Xiaoya Wu, Dongsheng Tang, Furou Lv, Qingxin Zhang, Haihua Xiao iD, Xiuli Hu

Advanced Healthcare Materials · 2026

DOI: 10.1002/adhm.202503875 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Jianxin Rong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Polymer Science and Engineering, School of Chemical Engineering, Hebei University of Technology, Tianjin, 300130, China. Hauptthemen laut MEDLINE: Paclitaxel, Prodrugs, Iridium. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Natural Science Foundation of Hebei Province, Government Guide the Development of Local Science and Technology Special Funds.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Stimuli‐cleavable prodrug technology offers a promising strategy to mitigate the severe systemic toxicity associated with conventional chemotherapy. However, its clinical translation is hindered by insufficient and nonspecific activation within heterogeneous tumors. To address this challenge, an ultrasound (US)‐activated nanoplatform (PDTC@Ir/PTX 2 ‐TK NPs) that couples a binuclear iridium sonosensitizer (Ir‐DPP‐Ir) with a reactive oxygen species (ROS)‐responsive paclitaxel prodrug (PTX 2 ‐TK), encapsulated in a self‐crosslinked polycarbonate (PDTC) carrier, is constructed. The PDTC carrier, which contains 1,2‐dithiolane, promotes stability and prevents premature drug leakage. Ir‐DPP‐Ir functions as a potent sonosensitizer, generating multiple ROS (e.g., •OH, 1 O 2 , O 2 −· ) under therapeutic ultrasound. The PTX 2 ‐TK prodrug maintains pharmacologically inert in normal tissues but is highly sensitive to ROS, thereby avoiding off‐target effects and ensuring tumor‐specific activation. Upon US irradiation, over 99% of PTX 2 ‐TK is effectively activated, addressing the critical bottleneck of tumor‐specific prodrug activation. This synergistic sonodynamic‐chemotherapy strategy achieves potent tumor eradication (95.8% inhibition) and stimulates a robust anti‐tumor immune response, while significantly minimizing systemic toxicity associated with conventional PTX administration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelProdrugsIridiumAnimalsMiceHumansReactive Oxygen SpeciesCell Line, TumorUltrasonic WavesUltrasonic TherapyMice, NudeMice, Inbred BALB CNeoplasmsFemale

Stichwörter der Autor:innen

dinuclear iridium (III)sonodynamic therapysono‐activatable prodrugstimuli‐responsive

Substanzen

PaclitaxelProdrugsIridiumReactive Oxygen Species

Autor:innen und Institutionen

  • Institute of Polymer Science and Engineering, School of Chemical Engineering, Hebei University of Technology, Tianjin, 300130, China.
  • Beijing National Laboratory for Molecular Sciences, Laboratory of Polymer Physics and Chemistry Institute of Chemistry, Chinese Academy of Sciences, Beijing, 100190, China.

ORCID-Profile: Haihua Xiao

Förderung

  • Natural Science Foundation of Hebei Province
  • Government Guide the Development of Local Science and Technology Special Funds

Zitieren

APA

Rong, J., Wu, X., Tang, D., Lv, F., Zhang, Q., Xiao, H., & Hu, X. (2026). Ultrasound‐Triggered Dinuclear Iridium Sonosensitizer Activates Paclitaxel Prodrug for Synergistic Sonodynamic‐Chemotherapy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202503875

Vancouver

Rong J, Wu X, Tang D, Lv F, Zhang Q, Xiao H, et al. Ultrasound‐Triggered Dinuclear Iridium Sonosensitizer Activates Paclitaxel Prodrug for Synergistic Sonodynamic‐Chemotherapy. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.202503875

BibTeX
@article{Rong2026,
  author = {Rong, Jianxin and Wu, Xiaoya and Tang, Dongsheng and Lv, Furou and Zhang, Qingxin and Xiao, Haihua and Hu, Xiuli},
  title = {Ultrasound‐Triggered Dinuclear Iridium Sonosensitizer Activates Paclitaxel Prodrug for Synergistic Sonodynamic‐Chemotherapy},
  journal = {Advanced Healthcare Materials},
  year = {2026},
  doi = {10.1002/adhm.202503875}
}
Kostenlos starten →